EHS management approach
We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
Search
Non-small cell lung cancer
Discover more about non-small cell lung cancer, including its symptoms and treatment options.
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
All the same, yet different – Ethnic Equality Month
Mohammed Samy, Human Pharma Marketing Team Lead from Amsterdam explains how ethnic diversity creates collective strength and sustainable growth
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Careers beyond borders
Careers beyond borders
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Tomorrow's leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
Partnership WHO Foundation mental health
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Mental Health
Human Pharma Clinical Pipeline Mental Health therapeutic area
Dirk Esser
Diverse, caring, collaborative - Dirk Esser on Boehringer Ingelheim
Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Partnering Interests in Retinal Health
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC